Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

Table 2 Patient disposition

Disposition, n (%)	Patients (N = 45)
Completed through week 24	42 (93.3)
Discontinued during the treatment phase	3 (6.7)
Consent withdrawn	2 (4.4)
Disease progression	1 (2.2)
Deaths*	1 (2.2)
Completed the study^†	37 (82.2)

*The patient who withdrew because of disease progression later died
^†Completed the study, including the follow-up phase, which was up to 37 days after the final ruxolitinib dose. One patient was lost to follow-up and four patients discontinued during the study for other reasons

ISSN: 1756-8722